

DDX41 recognizes RNA/DNA retroviral reverse transcripts and is critical for *in vivo* control of MLV infection

Spyridon Stavrou^{1*}, Alexya Aguilera¹, Kristin Blouch² and Susan R. Ross^{1#}

¹Department of Microbiology and Immunology, University of Illinois at Chicago, College of Medicine, Chicago, IL

²Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Microbiology, Philadelphia, PA

#Corresponding author

Email: srross@uic.edu

*Current address: Department of Microbiology and Immunology, State University of New York at Buffalo

Word count abstract:

Word count text:

Keywords: DEAD-box helicase; cGAS; cytosolic sensing; anti-viral interferon response; AML/MDS; RNA/DNA hybrid

1 **Abstract**

2 Host recognition of viral nucleic acids generated during infection leads to the activation
3 of innate immune responses essential for early control of virus. Retrovirus reverse transcription
4 creates numerous potential ligands for cytosolic host sensors that recognize foreign nucleic acids,
5 including single-stranded RNA (ssRNA), RNA/DNA hybrids and double stranded DNA (dsDNA). We
6 and others recently showed that the sensors cyclic GMP-AMP synthase (cGAS), dead-box helicase
7 41 (DDX41) and members of the Aim2-like receptor (ALR) family participate in the recognition of
8 retroviral reverse transcripts. However, why multiple sensors might be required and their relative
9 importance in *in vivo* control of retroviral infection is not known. Here we show that DDX41
10 primarily senses the DNA/RNA hybrid generated at the first step of reverse transcription, while
11 cGAS recognizes dsDNA generated at the next step. We also show that both DDX41 and cGAS are
12 needed for the anti-retroviral innate immune response to MLV and HIV in primary mouse
13 macrophages and dendritic cells (DC). Using mice with macrophage- or -specific knockout of the
14 DDX41 gene, we show that DDX41 sensing in DCs but not macrophages was critical for controlling
15 *in vivo* MLV infection. This suggests that DCs are essential *in vivo* targets for infection, as well as
16 for initiating the antiviral response. Our work demonstrates that the innate immune response to
17 retrovirus infection depends on multiple host nucleic acid sensors that recognize different
18 reverse transcription intermediates.

19

20 **Importance**

21 Viruses are detected by many different host sensors of nucleic acid, which in turn trigger
22 innate immune responses, such as type I IFN production, required to control infection. We show

23 here that at least two sensors are needed to initiate a highly effective innate immune response
24 to retroviruses – DDX41, which preferentially senses the RNA/DNA hybrid generated at the first
25 step of retrovirus replication and cGAS, which recognizes double-stranded DNA generated at the
26 2nd step. Importantly, we demonstrate using mice lacking DDX41 or cGAS, that both sensors are
27 needed for the full antiviral response needed to control *in vivo* MLV infection. These findings
28 underscore the need for multiple host factors to counteract retroviral infection.
29

30 **Introduction**

31 Retroviruses are major causes of disease in animals and humans. The initial immune response to
32 retroviruses is critical to the ability of organisms to clear infection, because once viral DNA
33 integrates into the host chromosomes, persistent infections arise, leading to
34 immunodeficiencies, cancers and other pathologies. The genomes of mammals and other species
35 encode many genes that restrict infectious retroviruses. Among the host anti-retroviral factors,
36 APOBEC3 proteins play a major role in restricting retrovirus infection, by cytidine deamination of
37 retroviral DNA and by blocking early reverse transcription (1-7).

38 The retrovirus RNA genome is converted by the viral reverse transcriptase (RT) enzyme first
39 to RNA/DNA hybrids using a tRNA to prime DNA synthesis and then to dsDNA. Reverse
40 transcription thus creates potential ligands for host sensors that recognize foreign nucleic acids.
41 Cellular recognition of these retroviral reverse transcripts activates the innate immune response.
42 For example, depletion of the host cytosolic DNA exonuclease Three Prime Repair Exonuclease 1
43 (TREX1), a DNA exonuclease, increases the type I interferon (IFN) response to HIV and MLV
44 infection (4, 8, 9). The TREX1-sensitive retroviral reverse transcripts are recognized by cellular
45 DNA sensors such as cGAS, DDX41 and ALR family members such as IFN-Induced 16 (IFI16) in
46 humans and IFI203 in mice (9-13).

47 cGAS produces the second messenger cyclic GMP-AMP (cGAMP) upon DNA binding, which
48 binds and activates Stimulator of IFN Genes (STING) (14-16). STING then translocates from the
49 endoplasmic reticulum to a perinuclear compartment and activates TANK-binding kinase 1 (TBK1)
50 which phosphorylates the transcription factor IFN regulatory factor 3 (IRF3) which in turn enters
51 the nucleus where it induces type 1 IFN transcription (17-19). DNA binding to DDX41 and the

52 ALRs also induces type I IFN production via the STING pathway (20). It is not understood how
53 DDX41, which belongs to a family of DEAD box helicase-containing genes commonly thought to
54 bind RNA, participates in the recognition of nucleic acid. Familial and sporadic mutations in
55 human DDX41 lead to acute myeloblastic leukemia and myelodysplastic syndromes, suggesting
56 that it also functions as a tumor suppressor (21, 22).

57 While many studies have shown that the loss of any one of these factors decreases the STING-
58 mediated IFN response to cytosolic DNA, it is not known why there are multiple sensors that
59 converge on the same pathway, particularly *in vivo*. Here we show that DDX41 recognizes the
60 RNA/DNA intermediate generated by reverse transcription and that DDX41 and cGAS act
61 additively to increase the IFN response and limit retroviral infection *in vivo*. Moreover, using mice
62 with cell type-specific knockout of DDX41, we show that DCs and not myeloid-derived cells are
63 likely the major sentinel cell targets of *in vivo* infection. These studies reveal why multiple nucleic
64 acid sensors are needed to control retroviral infection and underscore the importance of studying
65 their role in *in vivo* infection.

66

67 **Results**

68 **DDX41, IFI203 and cGAS play independent but additive roles in the response to MLV infection.**

69 We showed previously that MLV infection caused a rapid increase in IFN β RNA levels in murine
70 macrophages that is sensitive to the RT inhibitor ziduvodine and that Trex1 knockdown further
71 increased this response (4, 9). We also showed that depletion of DDX41, IFI203 or cGAS
72 diminished the IFN β response with and without Trex1 knockdown, that all three molecules bound
73 MLV reverse transcribed DNA and that IFI203 and DDX41 bound to each other and STING, but

74 not to cGAS (9). These data suggested that IFI203 and DDX41 work together in a complex to sense
75 reverse transcripts.

76 We hypothesized that DDX41/IFI203 and cGAS play additive but non-redundant roles in
77 the STING/IFN β activation pathway. To determine if DDX41/IFI203 and cGAS acted synergistically
78 to generate an anti-MLV response, we tested the effects of DDX41, IFI203, and STING knockdown
79 in bone marrow-derived macrophages (BMDMs) and DCs (BMDCs) isolated from cGAS knockout
80 (KO) mice that also lacked APOBEC3; APOBEC3 depletion leads to increased reverse transcript
81 levels and higher levels of IFN induction and thus greater assay sensitivity (4, 9). After siRNA-
82 mediated knockdown, the cells were infected with MLV and the IFN response determined at 2
83 hpi, the time of maximum response (4, 9). Despite the lack of cGAS in these cells, MLV infection
84 induced higher levels of IFN β RNA that was further increased by Trex1 knockdown (compare
85 mock to control to Trex1 siRNA in Fig. 1A), suggesting that additional sensors of retroviral nucleic
86 acid exist in sentinel cells. Ddx41 or Ifi203 knockdown in cGAS KO BMDMs and BMDCs diminished
87 the type I IFN response to the same level as Sting knockdown (Fig. 1A). These data show that the
88 full STING-dependent type I IFN response to MLV reverse transcripts requires both DDX41/IFI203
89 and cGAS.

90 The factor PQBP1 binds retroviral DNA upon infection and functions upstream of cGAS,
91 since cGAMP addition to PQBP1-or cGAS-depleted cells restores the type I IFN response (23)
92 (diagram in Fig. 1B). To determine if DDX41 worked upstream of cGAS, we tested whether cGAMP
93 also would rescue the IFN response in Ddx41/Ifi203 knockdown cells. siRNA-mediated depletion
94 of Ifi203 and Ddx41 plus Trex1 was carried out in NR9456 mouse macrophage cells; cGAS and
95 STING depletion served as positive and negative controls, respectively. At 24 hr post-siRNA

96 transfection, the cells were left untreated or transfected with cGAMP for 18 hr and then infected
97 with MLV for 2 hr. cGAMP addition did not restore the IFN β response in DDX41-, IFI203- or STING-
98 depleted cells (Fig. 1C). As expected, addition of cGAMP restored the IFN β response in cGAS-
99 depleted cells (Fig. 1C). Taken together with our previously published results, these data
100 suggested that DDX41/IFI203 functions independently of cGAS to activate the STING pathway
101 (pathway b in Fig. 1B) and that the induction of IFN by the two sensors is additive.

102

103 **DDX41 is a cytosolic sensor that acts upstream of IRF3 and TBK1.** DDX41 is found in both
104 the nucleus and cytoplasm (9). The ALR IFI16 senses herpes simplex virus DNA in the nucleus and
105 then migrates to the cytoplasm where it signals through STING (24, 25). The ultimate product of
106 reverse transcription is a dsDNA that is transported into the nucleus and integrates into the
107 chromosomes. Unintegrated retroviral DNA persists in the nucleus as 1- or 2-LTR circles. To
108 determine if DDX41 sensed nuclear retroviral dsDNA, we treated cells with the integrase inhibitor
109 raltegravir, which increases nuclear unintegrated viral dsDNA levels, and examined the IFN
110 response after MLV infection. Although raltegravir treatment dramatically increased the levels of
111 unintegrated nuclear viral DNA, evidenced by abundant 2-LTR circle formation, this treatment
112 had no effect on IFN β induction (Fig. S2A), supporting DDX41 sensing of retroviral reverse
113 transcription products predominantly in the cytoplasm.

114 To test whether DDX41 functioned downstream of STING, TBK1 or IRF3 (Fig. 1B), we
115 siRNA-depleted DDX41, cGAS or STING in NR9456 macrophages, infected them with MLV and
116 examined IRF3 (Ser396) and TBK1 (Ser172) phosphorylation at 2 hr post-infection (hpi);
117 lipopolysaccharide (LPS) treatment served as a positive control. While phospho-TBK1 and -IRF3

118 were induced in LPS-treated BMDMs and in Trex1-depleted BMDMs in response to MLV, siRNA
119 depletion of Ddx41, cGas or Sting ablated virus-induced TBK1 and IRF3 phosphorylation (Fig. 2).
120 Taken together, these data suggest that DDX41 works in the cytoplasm upstream of STING to
121 induce IFN.

122

123 **DDX41 recognizes RNA/DNA hybrid reverse transcription intermediates.** Retroviruses generate
124 several replication intermediates which could be sensed as foreign – tRNA-bound DNA/RNA
125 hybrids, ssDNA and dsDNA. We used three approaches to examine which reverse transcription
126 products were sensed by DDX41. First, to determine if DDX41 or cGAS bound to tRNA primer-
127 containing reverse transcription intermediates, 293T cells stably expressing the MLV receptor
128 MCAT1 were transiently transfected with DDX41 or cGAS constructs, infected with MLV and pull-
129 down experiments were performed. After pull-down, DNA was isolated from half of each sample
130 and subjected to PCR amplification with primers that detect early reverse transcripts (strong-stop
131 primers P_R and P_{U5}), while cDNA was prepared from the remaining half and amplified with P_R and
132 a 3' primer specific to tRNA^{pro} (P_{tRNA}), the tRNA used by MLV RT to prime reverse transcription
133 (Fig. 3A). DDX41 bound to >2-fold more tRNA^{pro}-containing reverse transcripts, while DDX41 and
134 cGAS equally precipitated a product that amplified strong stop DNA (Fig. 3B).

135 Second, we treated the DDX41- and cGAS-bound nucleic acids with RNaseH, which
136 degrades RNA in DNA/RNA hybrids as well as the tRNA primer, DNaseI, which cleaves dsDNA 100-
137 and 500-fold better than RNA/DNA hybrids and ssDNA, respectively, and RNaseA, which degrades
138 ssRNA under high salt conditions. DDX41 again more efficiently precipitated the RNA/DNA hybrid
139 and RNaseH treatment reduced the amount of DDX41-precipitated nucleic acid to 3%. In

140 contrast, RNaseH digestion only modestly affected cGAS-pulldown of the product amplified with
141 the P_R/P_{tRNA} primer pair, suggesting that DDX41 preferentially bound the RNA/DNA hybrid while
142 cGAS bound to tRNA primer-bound dsDNA generated after strand translocation (Fig. 3C, left
143 panel; see diagram in Fig. 4A). In support of this, DNaseI treatment abolished cGAS-mediated
144 pulldown of both the P_R/P_{tRNA}- and P_R/P_{U5}-amplifiable products, while DDX41-mediated
145 precipitation of nucleic acid (Fig. 3C, left panel and right panels) was affected to a lesser extent.
146 RNaseA digestion in high salt had no effect on any of the pulldowns.

147 Finally, we used a viral mutant lacking RNaseH activity. During reverse transcription, RT's
148 RNaseH moiety degrades the positive strand RNA genome after the synthesis of minus strand
149 DNA (Fig. 4A) (26). RNaseH mutations attenuates the RNaseH function without diminishing the
150 polymerase activity. RNaseH^{D542N} synthesizes tRNA^{pro}-primed (-) strand strong stop DNA while
151 retaining ~10% the wild type levels of RNaseH enzymatic activity. As a result, the RNA remains
152 "frozen" in a DNA/RNA hybrid and (-) strand strong stop DNA does not efficiently translocate to
153 the 3' end of the viral RNA to initiate full-length (-) strand DNA synthesis (Fig. 4A) (27, 28). We
154 engineered the D542N mutation into a MLV molecular clone (MLV^{D542N}) and used this virus to
155 infect NR9456 cells. MLV^{D542N} generated almost 3-fold more reverse transcription products
156 retaining the tRNA primer than did the wild type virus, reflecting its poorer ability to translocate
157 the negative strand strong-stop DNA to the 5' end of the RNA and degrade the tRNA primer, and
158 its known increased DNA polymerase activity relative to wild type virus (P_R-P_{tRNA}, Fig. 4B) (27, 29).
159 The mutation dramatically attenuated reverse transcription detected with the strong-stop (P_R-
160 P_{U5}) primers compared to wild type virus, since these primers detect R-U5 DNA present in (-) and
161 (+) strand strong stop as well as full-length (-) strand DNA; late reverse transcription (P_{3'R}-P_{3'L})

162 products were also reduced compared to wild type virus (Fig. 4B). Interestingly, Trex1 depletion
163 led to increases in reverse transcription products retaining tRNA from both the wild type and
164 MLV^{D542N} viruses, suggesting that negative-strand strong-stop DNA is also degraded by this
165 cellular exonuclease (Fig. 4B); it has been previously shown that TREX1 degrades ssDNA and
166 dsDNA and DNA in RNA/DNA hybrids (8, 30, 31).

167 To determine whether DDX41 or cGAS was better able to recognize the early DNA/RNA
168 reverse transcription product, we infected NR9456 cells or primary BMDCs with MLV^{D542N} after
169 treatment with Trex1 siRNA alone, or in combination with Sting, Ddx41 or cGas siRNAs. MLV^{D542N}
170 caused about a 5- and 2-fold increase in the IFN response compared to wild type virus in the
171 Trex1 siRNA-treated and untreated NR9456 cells, respectively (left panel, Fig. 4C). DDX41
172 knockdown diminished the response to both viruses to the same levels as seen with STING
173 knockdown in both NR9456 cells and primary BMDCs (Fig. 4C). Depletion of cGAS reduced but
174 did not completely abrogate the TREX1-dependent response to MLV^{D542N} in NR9456 or primary
175 BMDCs (Fig. 4C). The response to the RNaseH mutant virus in cGAS-deficient cells was likely due
176 to DDX41-mediated recognition of the RNA/DNA hybrid in these cells (Fig. 4C).

177 The results from these 3 complementary approaches indicate that DDX41 preferentially
178 senses the RNA/DNA hybrid generated during the earliest stage of reverse transcription while
179 cGAS preferentially recognizes dsDNA generated at the next step.

180

181 **DDX41 is required for the IFN response in both macrophages and DCs.** Macrophages and DCs
182 have both been implicated in the anti-retroviral innate immune response. We examined DDX41
183 expression in BMDMs and BMDCs and found that it was expressed in both cell types at both the

184 RNA and protein level (Fig. 5A). Interestingly, in contrast to DDX41 expression, cGas and Ifi203
185 RNA levels and cGAS protein levels were significantly higher in wild type BMDMs than in BMDCs,
186 suggesting that the sensors used to detect nucleic acid might be cell type-specific (Fig. 5A). The
187 lack of anti-IFI203-specific antisera prevented us from determining whether its protein levels in
188 BMDMs and BMDCs reflected the RNA levels.

189 To determine whether DDX41 was important for IFN-induction in these cells types, we
190 used mice with a knocked-in floxed DDX41 allele, in which the loxP sites flank exons 7 and 9 (Fig.
191 S4A). We crossed these mice with CMV-Cre mice, but no complete KO pups were generated,
192 suggesting that germline loss of Ddx41 causes embryonic lethality. We then crossed these mice
193 with CD11cCre and LyCre transgenic mice to generate DC- and myeloid lineage-specific KOs,
194 respectively. We also used BMDMs and BMDCs from cGas KO mice and *Sting^{gt/gt}* mice, which
195 encode a mutant STING protein incapable of signaling and whose protein levels are greatly
196 reduced (32). BMDMs from the LyCre-DDX41 and BMDCs from the CD11cCre-DDX41 mice were
197 deficient in DDX41 RNA and protein but had wild type levels of STING and cGAS (Figs. 5B and
198 S4B). Additionally, DDX41 protein levels were significantly higher in the cGas KO BMDCs but not
199 BMDMs (Figs. 5B and S4B). Basal levels of IFN were not also not affected by loss of DDX41 (Fig.
200 S4C) and FACS analysis demonstrated that DDX41 deficiency did not affect overall percentages
201 of peripheral blood DCs or macrophages in the CD11cCre-DDX41 or LyCre-DDX41 mice (Fig. S4D).
202 To ensure that DDX41 loss did not affect all innate immune responses, BMDCs and BMDMs from
203 CD11cCre-DDX41 and LyCre-DDX41 mice were treated with the Toll-like receptor (TLR) 4 ligand
204 LPS, the TLR3/MAVS pathway ligand poly (I:C) and cGAMP; cells from cGas KO, *Sting^{gt/gt}* and
205 C57BL/6N mice served as controls. The response to LPS and poly (I:C) were similar to wild type in

206 CD11cCre-DDX41 BMDCs, LyCre-DDX41 BMDMs, cGas KO and *Sting*^{gt/gt} BMDMs and BMDCs (Fig.
207 S4E). cGAMP responses were reduced only in *STING*^{gt/gt} cells, as previously reported (33).

208 We then used these cells to examine the response to MLV infection. BMDCs or BMDMs
209 lacking DDX41 mice showed little or no increase in type I IFN RNA (Fig. 6A) or protein (Fig. S5A)
210 in response to MLV, even when TREX1 levels were reduced by siRNA treatment. BMDCs and
211 BMDMs from *Sting*^{gt/gt} and cGas KO mice also had an abrogated antiviral IFN β response under
212 the same conditions (Figs. 6A, S5A). We also tested whether the response to HIV-1 was defective
213 in the various mouse knockout cells, using pseudoviruses bearing the ecotropic MLV envelope;
214 the IFN β RNA response to HIV was diminished in both DDX41 and cGAS KO BMDMs and BMDCs
215 (Fig. 6B). Thus, both sensors are required for the full type I IFN response to both MLV and HIV in
216 mouse cells.

217 The TREX1-/DDX41-dependent IFN β response to MLV infection was much higher in
218 BMDCs than in BMDMs; there was a 2000-fold increase in IFN β RNA in BMDCs compared to
219 BMDMs, where the response was about 40-fold (compare y axes in Fig. 6A and 6B). To determine
220 if this was due to increased infection, we isolated splenic DCs and macrophages from MLV-
221 infected C57BL/6 mice at 16 days post-inoculation (dpi), as well as BMDCs and BMMs from mice
222 of all the genotypes infected *ex vivo* with MLV. Integrated MLV DNA was analyzed by qPCR with
223 a B1 repeat- and MLV LTR-specific primers. MLV infection of DCs was about one order of
224 magnitude higher than that of macrophages, after either *in vivo* and *ex vivo* infection,
225 independent of the mouse genotype (Figs. 6C and S6, respectively). Thus, while macrophages can
226 be infected, sustain reverse transcription and mount a response to viral nucleic acids, DCs are
227 more infected and respond more robustly to infection.

228

229 **Full suppression of MLV infection *in vivo* requires both DDX41 and cGAS.** To determine whether
230 DDX41 and cGAS functioned *in vivo* to suppress infection, we subcutaneously inoculated the
231 CD11cCre-DDX41 and cGas KO mice with MLV and measured infection levels in the draining
232 lymph node; wild type (DDX41^{f/f} mice without Cre) and Sting^{gt/gt} mice served as controls. The
233 CD11cCre-DDX41 and cGAS knockout mice showed significantly higher levels of infection than
234 the wild type mice, while Sting^{gt/gt} mice had the highest level of infection (Fig. 7A).

235 Next, we tested whether DDX41 and cGAS acted synergistically *in vivo*. We treated
236 CD11cCre-DDX41 and wild type mice with cGAS siRNAs and cGas knockout and wild type mice
237 with DDX41 siRNAs; mice injected with the *in vivo* transfection reagent InvivoFectamine alone
238 served as controls. At 48 hr post-siRNA treatment, the mice were infected with MLV in the same
239 footpad and at 24 hpi, RNA was isolated from the draining lymph node and examined for MLV
240 RNA levels (Fig. 7A) and the extent of gene knockdown (Fig. S7). CD11cCre-DDX41 mice that
241 received the cGAS siRNA and cGAS knockout mice that received the DDX41 siRNA were infected
242 at >8-fold higher levels than wild type mice receiving no siRNA and at >3-fold higher levels than
243 wild type mice receiving the DDX41 or cGAS siRNA. Infection levels in the CD11cCre-DDX41/cGAS
244 siRNA group were not statistically different than the cGAS KO/DDX41 siRNA group (Fig. 7A). Wild
245 type mice receiving the DDX41 or cGAS siRNAs were >2-fold more infected than untreated wild
246 type mice and were not statistically different from each other. Sting^{gt/gt} mice had the highest
247 levels of infection, about 2-fold higher than cGAS KO/DDX41 siRNA or CD11cCre-DDX41/cGAS
248 siRNA mice.

249 We also examined whether DDX41 expression in BMDMs or BMDCs was important to
250 suppress long term *in vivo* infection. Newborn offspring from crosses between LyCre-DDX41+/-
251 and CD11cCre-DDX41 +/- mice as well as newborn C7BL/6, *Sting*^{gt/gt} and cGAS KO pups were
252 inoculated with MLV and at 16 dpi, virus titers in their spleens were measured; this timepoint has
253 been used extensively by us and others to examine MLV infection (4, 5, 7, 9, 34, 35). The
254 genotyping of the intercrossed mice was carried out subsequent to measuring the virus titers.
255 We thus compared infection levels between mice with total lack of DDX41 due to full knockout
256 of the gene in the specific compartment to mice with only one knockout allele and to mice with
257 no knockout of DDX41 (Fig. S6B).

258 Mice with complete knockout of DDX41 in DCs showed 5-fold higher infection than either
259 wild type mice or mice heterozygous for the DDX41 knockout allele in this cell type (Fig. 6). cGas
260 KO mice were also more infected, also to about 5-fold higher levels than wild type mice and the
261 level of infection was the same as the CD11cCre-DDX41 mice (Fig. 6). In contrast, *Sting*^{gt/gt} mice
262 were most highly infected with MLV, about 10-fold higher than wild type mice (Fig. 6). This
263 confirms that cGAS and DDX41 are both required for full sensing of retroviral reverse transcripts
264 and for the control of virus *in vivo*. Surprisingly, MLV infection of mice with complete knockout
265 of DDX41 in macrophages was the same as wild type or heterozygotes (Fig. 6). Thus, although
266 DDX41 sensed MLV infection in macrophages *in vitro* and *ex vivo*, this response *in vivo* was not
267 sufficient to control infection.

268

269 **Discussion**

270 The host factor APOBEC3, which both blocks reverse transcription and causes lethal mutation of
271 the viral genome, is likely the first lines of defense against retroviruses, although incoming
272 retroviruses do generate ligands that activate the innate immune system (9). We recently
273 proposed that the major role for cytosolic sensing of reverse transcripts that escape the
274 APOBEC3-mediated reverse transcription block is to induce expression of ISGs, including
275 APOBEC3 itself (9). The most highly studied of these sensors, cGAS, is clearly a critical component
276 of the foreign DNA recognition pathway, leading to STING activation and the type I IFN response.
277 However, the role of other sensors implicated in the response to DNA generated during pathogen
278 infection remains controversial. These include DDX41 as well as members of the ALR family (4,
279 10, 13, 36, 37). Here we show that DDX41 is a critical sensor of viral nucleic acids generated during
280 reverse transcription and is required to control *in vivo* infection.

281 Retroviruses are unique in generating multiple different forms of nucleic acid during their
282 replication in the cytoplasm which can be recognized as “foreign” by the host cell. DDX41 is likely
283 recognizing the DNA/RNA hybrid generated in the first step of retrovirus replication and cGAS
284 the dsDNA generated after strand translocation. While we showed that DDX41 and cGAS KO
285 BMDMs or BMDCs showed diminished responses to transfected synthetic dsDNA or DNA/RNA
286 molecules, DDX41 preferentially precipitated RNaseH-sensitive, DNA/RNA hybrid reverse
287 transcripts generated during MLV infection and only depletion of DDX41 specifically reduced the
288 IFN response to the RNaseH mutant virus, which generates more RNA/DNA hybrids than does
289 wild type MLV. In contrast, cGAS precipitated DNaseI-sensitive reverse transcripts and cGAS-
290 depletion did not completely abrogate the type I IFN response to the RNaseH mutant generated
291 at the 1st step of reverse transcription. Whether the presence of the tRNA primer bound to

292 DNA/RNA hybrids or dsDNA plays a role in the recognition by DDX41 or cGAS, respectively, is
293 currently not know.

294 *DDX41* belongs to a family of RNA helicases, with distinct DEAD/H box (Asp-Glu-Ala-Asp/His)
295 domains, whose members have been implicated in translation, ribosome biogenesis, nuclear-
296 cytoplasmic transport, organelle gene expression and pre-mRNA splicing (38-40). *DDX41* was
297 recently identified as a tumor suppressor gene in familial and sporadic myelodysplastic
298 syndrome/acute myeloid leukemia (MDS/AML), as well as other hematological malignancies (21,
299 39, 41). In MDS/AML, *DDX41* is thought to interact with spliceosomal components and alter
300 splicing, resulting in the inactivation of tumor suppressor genes or alterations in the balance of
301 gene isoforms, although whether this occurs through protein-RNA, protein-DNA or protein-
302 protein interactions is not known. Our data showing that *DDX41* interacts with RNA/DNA hybrids
303 are consistent with the known ability of DEAD box proteins' recognition of RNA and suggest that
304 *DDX41* may have evolved an anti-viral cytoplasmic activity that takes advantage of its unique
305 ability to interact with both RNA and DNA, as well as proteins. Another DEAD-box helicase, *DDX3*,
306 was also recently implicated in the sensing of HIV RNA in DCs (42). However, *DDX3* sensed
307 abortive RNA transcribed from integrated proviruses, whereas *DDX41* sensing occurred in the
308 presence of the integrase inhibitor raltegravir, confirming that it works at a very early step of
309 infection.

310 A previous study suggested that *DDX41* might be the initial cytosolic sensor in BMDMs
311 and that type I IFNs induced by *DDX41* sensing lead to increased expression of cGAS, which is an
312 ISG (43). However, at 2 hr pi, cGAS- and *DDX41*-deficient cells showed similar decreased IFN β
313 RNA levels after MLV infection, suggesting that both sensors are needed for the initial response.

314 We showed previously that DCs get infected by MLV (5) and here we demonstrate that DDX41 in
315 DCs but not macrophages was required for *in vivo* control of virus infection. The innate immune
316 response initiated by DDX41 sensing of MLV in DCs may be due to higher levels of infection than
317 in macrophages or because DCs are more effective at initiating antiviral responses. Whether the
318 cGAS-dependent response is also required to control *in vivo* infection primarily in DCs is not
319 known. Nevertheless, the results presented here contradict studies suggesting that DCs do not
320 get infected but serve only as carriers that deliver intact retroviral virions to lymphocytes (44-
321 46).

322 Previous work suggested that only cGAS is important for sensing retroviruses via the
323 STING pathway (12, 47). These studies used VSV G protein-pseudotyped HIV or MLV cores. Both
324 HIV and MLV naturally enter cells from a neutral compartment and it is possible that the use of
325 VSV G, which directs entry to an acidic compartment, might affect the accessibility of different
326 sensors to the reverse transcription complex. Additionally, these studies tested embryonic
327 fibroblasts or BMDMs. However, as we demonstrated previously and our *ex vivo* and *in vivo*
328 studies here demonstrate, DCs are likely the important targets of retroviruses (5, 48). Indeed, we
329 also show here that endogenous cGAS expression in DCs, the relevant cell type for controlling
330 MLV infection *in vivo*, is ~4-fold lower than that seen in macrophages, which could also account
331 for the differences in our results with previous studies. Similar differences in cGAS expression
332 occur in human macrophages and DCs (49).

333 Finally, earlier studies did not examine the effects of the different sensors on *in vivo*
334 infection. We show here that effective *in vivo* control of MLV infection via the STING pathway
335 requires both DDX41 and cGAS. However, as we and others have shown, the retrovirus capsid

336 likely protects the reverse transcription complex from host sensors and other restriction factors,
337 including APOBEC3 proteins (9, 50). This may explain why mice lacking DDX41 or cGAS show only
338 5-fold higher infection than wild type mice; even STING-deficient mice show only 10-fold higher
339 infection (Fig. 7) (9). Our data are consistent with a requirement for both DDX41 and cGAS, the
340 former perhaps in complex with IFI203, to achieve the full antiviral IFN response to retroviral
341 reverse transcripts not protected by capsid or blocked by APOBEC3 proteins. Whether DDX41
342 requires interaction with IFI203 to achieve maximum effect *in vivo* will also be important to
343 determine; however, *Ifi203* shares a high degree of identity in the noncoding as well as coding
344 regions with several other genes in the *ALR* locus, making a gene-specific knockout difficult to
345 achieve (51). How nucleic acid-bound DDX41 activates STING is also not yet understood, although
346 the two molecules are known to directly bind each other (9, 13)

347 Our data suggest that there are multiple cytosolic sensors that recognize the different
348 types of nucleic acids generated during retrovirus infection. Understanding the initial host
349 response to infection by retroviruses is critical to our ability to determine how these viruses
350 establish persistent infection as well the discovery of novel approaches to intervene in these
351 infections.

352

353 **Experimental Procedures**

354 **Mice**

355 Mice were bred at the University of Pennsylvania and the University of Illinois at Chicago. DDX41-
356 flp mice (C57BL/6N) were constructed by TaconicArtemis GmbH and were derived by the
357 University of Pennsylvania Transgenic & Chimeric Mouse Facility from *in vitro* fertilization of

358 C57BL/6N embryos with sperm from a single male. LyCre (B6.129P2-Lyz2tm1(cre)lfo/J) and
359 *Sting^{gt/gt}* (C57BL/6J-Tmem173gt/J) mice were purchased from the Jackson Laboratory. CD11cCre
360 mice (B6.Cg-Tg(Itgax-cre)1-1Reiz/J) were provided by Yongwon Choi and cGAS knockout mice by
361 Michael Diamond and Skip Virgin (52). Apobec3 knockout mice were previously described (53).
362 cGas/Apobec3 double knockout mice were generated by inter-crossing the two strains. All mice
363 were housed according to the policies of the Institutional Animal Care and Use Committee of the
364 University of Pennsylvania and of the Animal Care Committee of the University of Illinois at
365 Chicago; all studies were performed in accordance with the recommendations in the Guide for
366 the Care and Use of Laboratory Animals of the National Institutes of Health. The experiments
367 performed with mice in this study were approved by the U. Pennsylvania IACUC (protocol
368 #801594) and UIC ACC (protocol #15-222).

369

370 **FACS analysis and sorting**

371 Peripheral blood mononuclear cells were stained with anti-mouse F4/80-FITC (Biolegend) and
372 anti-mouse CD11c-PE (BD Bioscience) antibodies. Cells were processed using a Beckman Coulter
373 Cyan ADP. Results were analyzed using FlowJo software.

374

375 **Virus**

376 Moloney MLV and MLV^{glycoGag} mutant viruses were harvested from stably infected NIH3T3
377 fibroblasts, as previously described (54). All virus preparations were titered on NIH3T3 cells and
378 analyzed by RT-qPCR for viral RNA levels as previously described (4). To generate the RNaseH
379 mutant virus, the D524N mutation previously described by Blain and Goff (27) was introduced

380 into the WT MLV infectious clone p63.2 (55) by site-directed mutagenesis using the Quickchange
381 II XL site directed mutagenesis kit (Agilent Technologies) and the primers 5'-
382 ACCTGGTACACGAATGGAAGCAGTCTCTTAC-3'/5'-GTAAGAGACTGCTTCCATTCGTGTACCAGGT-3';
383 the mutation was verified by sequencing. The p63.2 and p63.2^{D524N} plasmids were transfected in
384 293T cells using Lipofectamine 3000 (Invitrogen). The media of the transfected cells were
385 harvested 48 hours post-transfection, centrifuged at 500g for 10 minutes at 4°C, filtered through
386 a 0.45µm filter and treated with DNaseI recombinant RNase Free (Roche). Virus levels were
387 determined by the QuickTiter™ MuLV Core Antigen Elisa Kit (MuLV p30) (Cell Biolabs, Inc) and by
388 titering on NIH 3T3 cells stably transfected with pRMBNB, which expresses the MLV *gag* and *pol*
389 genes (28).

390

391 **BMDM and BMDC cultures**

392 BMDMs and BMDCs were isolated from hind limbs of 10- to 12-week-old cGas KO, *Sting*^{gt/gt},
393 *LyCre-DDX41*, *CD11cCre-DDX41* and C57BL/6 mice as previously described (56). BMDMs were
394 cultured in DMEM supplemented with 10% FBS, 10ng/ml Macrophage Colony Stimulating Factor
395 (Invitrogen), 1 mM sodium pyruvate, 100 U/ml penicillin and 100 µg/ml streptomycin and were
396 harvested 7days after plating and were seeded in 96-well plates for infection assays. BMDCs were
397 cultured in RPMI supplemented with 5% FBS and differentiated with recombinant murine
398 granulocyte-macrophage colony-stimulating factor (20 ng/ml; Invitrogen). Both procedures
399 result in cultures that are ~80% - 85% pure.

400

401 **cGAMP stimulation of macrophages**

402 Knockdowns with the indicated siRNAs were performed in NR9456 macrophages (immortalized
403 macrophage cell line derived from C57BL/6 wild type mice) (57) (BEI Resources, NIAID, NIH) using
404 RNAiMAX, as previously described (9). The next day, cells were transfected with Lipofectamine
405 2000 (Invitrogen) and 4ug of cGAMP (Invivogen), 16 hrs later the cells were infected with
406 MLV^{glycoGag} and harvested 2 hpi. RNA isolation and qPCR analysis was performed as previously
407 described (9).

408

409 **Virus infection of macrophages and DCs**

410 NR9456 macrophages, BMDMs and BMDCs were siRNA-transfected. Forty-eight hrs after
411 transfection, the cells were infected with wild type, MLV^{glycoGag} or D542N mutant M-MLV (MOI of
412 2) and harvested at the indicated times after infection. For some experiments, the cells were
413 treated with 200nM raltegravir for 2 hr prior to infection and then infected with MLV^{glycoGag} virus
414 in the presence of drug. Cells were harvested 2 hpi; RNA isolation and RT-PCR were performed
415 as previously described (9). Primers used for detection of actin, Trex1 and IFN β were previously
416 described (4, 58). Primers to amplify the MLV 2LTR closed circles are 5'-
417 GAGTGAGGGGTTGTGGGCTCT-3'/5'-ATCCGACTTGTGGTCTCGCTG-3' (59). Primers used to amplify
418 late reverse transcripts (P_{3'R}/P_{3'L}) are 5'-TAACGCCATTTTGCAAGGCA-3'/5'-
419 GAGGGGTTGTGGGCTCTTTT-3'; strong-stop DNA primers were reported previously (4).

420

421 **BMDM and BMDC treatment with synthetic ligands**

422 BMDMs and BMDCs isolated from C57BL/6, Sting^{gt/gt}, cGas KO, LyCre-DDX41, CD11c DDX41 mice
423 were transfected with 2 ng/ μ l poly IC (Sigma) and 4 ng of cGAMP using Lipofectamine 3000; cells

424 were also treated with 1 ng/ μ l LPS (Sigma). The cells were harvested at 6 hr post-treatment. RNA
425 was isolated and cDNA was generated using Superscript III kit (Invitrogen). RT-PCR was performed
426 to measure IFN β RNA levels, as previously described (4).

427

428 **siRNA knockdown and knockdown verification**

429 NR-9456, BMDMs and BMDCs were transfected with the indicated siRNAs (9) using
430 Lipofectamine RNAiMAX reagent (Invitrogen). RNA was isolated using the RNeasy Mini Kit
431 (Qiagen). All siRNAs used in this study were previously shown to be on-target and to decrease
432 both RNA and protein levels (9). cDNA was made using the SuperScript III First Strand Synthesis
433 System for RT-PCR (Invitrogen). RT-PCR was performed using the Power SYBR Green PCR master
434 mix kit (Applied Biosystems). Primers for the verification of the knockdowns have been previously
435 described (4, 9).

436

437 **IFN β ELISAs**

438 BMDMs and BMDCs were transfected with a control- or a Trex1-specific siRNA using
439 Lipofectamine RNAiMAX reagent (Invitrogen). Cells were then infected with MLV^{glycoGag} and the
440 culture media was harvested 4 hpi. The levels of IFN β in the culture media were measured using
441 the LEGEND MAXTM Mouse IFN β ELISA kit (Biolegend) per manufacturer's recommendation.

442

443 **HIV pseudoviruses**

444 Retroviral vectors bearing the Moloney MLV Env and HIV (pNL4-3) cores were produced by
445 transient transfection into 293T cells using Lipofectamine 3000 (Invitrogen), as previously

446 described (9). Pseudoviruses were harvested at 48 hpi and the pseudoviruses were treated with
447 DNaseI (20u/ml for 45min at 37°C) (Roche) and concentrated using AMICON columns.

448

449 **Nucleic acid pulldowns**

450 DDX41myc/his, IFI203-HA and cGAS-V5 plasmids have been previously described (9, 60).
451 293MCAT cells transfected with pcDNA3.1 (empty vector), cGAS-V5, and DDX41myc/his, were
452 infected with virus and at 4 hpi, the cells were cross-linked with 1% formaldehyde in media. Cross-
453 linking was quenched with 2.5M glycine, extracts prepared and then incubated overnight with
454 anti-myc- or anti-HA-agarose beads (Sigma) or anti-V5 antibody (Invitrogen) with G/A-agarose
455 beads (SantaCruz). The beads were washed with high-salt buffer (25mM Tris-HCl, pH 7.8, 500mM
456 NaCl, 1mM EDTA, 0.1% SDS, 1% TritonX-100, 10% glycerol) and with LiCl buffer (25mM Tris-HCl,
457 pH 7.8, 250mM LiCl, 0.5% NP-40, 0.5% Na-deoxycholate, 1mM EDTA, 10% glycerol). The
458 immunoprecipitated nucleic acid was eluted from the beads at 37°C in 100mM Tris-HCl, pH 7.8,
459 10mM EDTA, 1% SDS for 15 min and the protein-nucleic acid cross-linking was reversed by
460 overnight incubation at 65°C with 5M NaCl. The eluted nucleic acid was purified using the DNeasy
461 Kit (Qiagen) and analyzed with RT-PCR strong stop primers (primers P_R and P_{U5} in Fig. 3A) or 3'LTR
462 primers P_{3'R}-P_{3'L} in Fig. 4A) (4). For analysis of the tRNA-bound MLV nucleic acid, the same
463 procedure was used, except the eluted nucleic acid was reverse transcribed prior to PCR with the
464 P_R primer and another primer that annealed to nt 39-57 in tRNA^{pro} (P_{tRNA} in Fig. 3A) (5'-
465 GCTCTCCAGGGCCCAAGTT-3')(61). For the nuclease treatments, after the nucleic acids were
466 released from the protein cross-link, they were ethanol precipitated and treated at 37°C with 50u
467 RNase A (Thermo) for 20min in the presence of 300mM NaCl, 4u DNase I (Roche) with the

468 reaction buffer provided with the enzyme for 20min or 3u of RNase H (Thermo) for 20min in the
469 reaction buffer provided with the enzyme. Samples were digested with proteinase K and phenol-
470 chloroform extracted and the nucleic acids were subjected to qPCR analysis as described earlier
471 in this section.

472

473 **MLV infection levels**

474 NR9456 cells were infected with WT or D542N virus and 2hrs hpi, cellular DNA and RNA were
475 isolated. RNA was reverse transcribed using a Superscript III kit (Invitrogen) and the resultant
476 cDNA was used for quantitative PCR using the P_R-P_{trNA} primers. DNA was subjected to
477 quantitative PCR using the P_R-P_{U5} and the P_{3'LTRF}-P_{3'LTRR} primers. Bone marrow from C57BL/6 mice
478 was isolated and differentiated to BMDMs and BMDCs. BMDCs and BMDMs were infected with
479 MLV (0.1 MOI/cell). Cells were harvested at 24 and 48 hpi. For analysis of cell subset infection in
480 vivo, newborn mice were infected i.p. with MLV. At 16 dpi, splenocytes were isolated and FAC-
481 sorted directly into 15ml collection tubes using a MoFlo Astrios™ (Beckman Coulter, Brea, CA) at
482 the UIC Cell Sorting Facility; anti-F4/80-FITC and -CD11c-PE was used to distinguish macrophages
483 and DCs, respectively. DNA was isolated by using the DNeasy Kit (Qiagen). Quantitative PCR was
484 performed to measure integrated MLV DNA using the following primers: 5'-
485 CCTACTGAACATCACTTGGGG-3'/5'-GTTCTCTAGAACTGCTGAGGGC-3' and normalized to GAPDH.

486

487 **Western Blots**

488 Protein extracts from the BMDMs and BMDCs were run on 10% SDS-polyacrylamide gels and
489 transferred to PVDF Immobulon membranes (Thermo). Rabbit anti-STING, anti-cGAS, anti-

490 phosphoIRF3 (Ser 396), anti-IRF3, anti-TBK1 and anti-phosphoTBK1 (Ser 172) and HRP-
491 conjugated anti-rabbit antibodies, all from Cell Signaling Technology, mouse monoclonal anti-
492 DDX41 (SantaCruz Biotechnology) and -mouse antibody (Sigma Aldrich) were used for detection,
493 using either ECL Western blot detection reagent or ECL prime Western blot detection reagent
494 (GE Healthcare Life Sciences).

495

496 ***In vivo* siRNA knockdown**

497 siRNAs were purchased from Ambion (Life Technologies). The InvivoFectamine 3.0 Starter Kit
498 (Invitrogen, Life Technologies) was used according to the manufacturer's protocol. Each siRNA
499 solution (2.5nmol/ μ l) was combined with complexation buffer and InvivoFectamine reagent for
500 30 minutes at 50°C. Footpad injections of the siRNA/InvivoFectamine complex or InvivoFectamine
501 alone were carried out 48h prior to infection with MLV (2.5×10^5 IC/mouse) in the same footpad.
502 Each mouse received 20nmol of siRNA. After 24 hpi, mice were euthanized and draining lymph
503 node tissues were collected and harvested for RNA isolation. MLV RNA levels were measured by
504 RT-qPCR, as previously described (34). Knockdown of the siRNA-targeted gene was also verified
505 by RT-qPCR as described above.

506

507 ***In vivo* infections**

508 For systemic infections, two-day old mice (C57BL/6N, cGAS KO, STING^{gt/gt} and the tissue-specific
509 DDX41 KO mice described in Suppl. Table 1) were infected intraperitoneally with 2×10^4 infectious
510 center (IC) units of MLV and then harvested at 18 days pi and virus titers in spleens were
511 measured by IC assays, as previously described (4). The *in vivo* infection studies were performed
512 both at the University of Pennsylvania and the University of Illinois. The DDX41 knockout mice

513 were housed side-by-side with the STING^{gt/gt} and cGAS mice, and crossed with BL/6N mice from
514 our colony.

515

516 **Statistical Analysis**

517 Each experiment was done with 3 technical replicates/experiment. Data shown is the average of
518 at least 3 independent experiments, or as indicated in the Fig. legend. Statistical analysis for the
519 various experiments was performed using the GraphPad/PRIZM software. All raw data are
520 deposited in Mendeley dataset accession <http://dx.doi.org/10.17632/j4mgm4v9t3.1>.

521

522 **Acknowledgements:** We thank Gerard Zurawski for help in obtaining the DDX41-flox mice, Skip
523 Virgin and Mike Diamond for the cGAS KO mice, Yongwon Choi for the CD11cCre mice, the
524 Transgenic and Chimeric Mouse Facility of the University of Pennsylvania for generating the
525 DDX41-flox mice by *in vitro* fertilization, Lorraine Albritton for the Moloney MLV construct, Vinay
526 Pathak for the gag-pol (pRMBNB) construct and David Ryan for help with maintaining the
527 different mouse lines. Raltegravir was obtained through the NIH AIDS Reagent Program and
528 NR9456 cells were obtained from the BEI Resources, NIAID, NIH.

529

530 **References**

- 531 1. **Harris RS, Hultquist JF, Evans DT.** 2012. The restriction factors of human immunodeficiency virus.
532 The Journal of biological chemistry **287**:40875-40883.
- 533 2. **Okeoma CM, Low A, Bailis W, Fan HY, Peterlin BM, Ross SR.** 2009. Induction of APOBEC3 in vivo
534 causes increased restriction of retrovirus infection. J Virol **83**:3486-3495.
- 535 3. **MacMillan AL, Kohli RM, Ross SR.** 2013. APOBEC3 inhibition of mouse mammary tumor virus
536 infection: the role of cytidine deamination versus inhibition of reverse transcription. J Virol
537 **87**:4808-4817.

- 538 4. **Stavrou S, Nitta T, Kotla S, Ha D, Nagashima K, Rein AR, Fan H, Ross SR.** 2013. Murine leukemia
539 virus glycosylated Gag blocks apolipoprotein B editing complex 3 and cytosolic sensor access to
540 the reverse transcription complex. *Proc Natl Acad Sci U S A* **110**:9078-9083.
- 541 5. **Low A, Okeoma CM, Lovsin N, de las Heras M, Taylor TH, Peterlin BM, Ross SR, Fan H.** 2009.
542 Enhanced replication and pathogenesis of Moloney murine leukemia virus in mice defective in the
543 murine APOBEC3 gene. *Virology* **385**:455-463.
- 544 6. **Takeda E, Tsuji-Kawahara S, Sakamoto M, Langlois MA, Neuberger MS, Rada C, Miyazawa M.**
545 2008. Mouse APOBEC3 restricts friend leukemia virus infection and pathogenesis in vivo. *J Virol*
546 **82**:10998-11008.
- 547 7. **Santiago ML, Montano M, Benitez R, Messer RJ, Yonemoto W, Chesebro B, Hasenkrug KJ,**
548 **Greene WC.** 2008. Apobec3 encodes Rfv3, a gene influencing neutralizing antibody control of
549 retrovirus infection. *Science* **321**:1343-1346.
- 550 8. **Yan N, Regalado-Magdos AD, Stiggelbout B, Lee-Kirsch MA, Lieberman J.** 2010. The cytosolic
551 exonuclease TREX1 inhibits the innate immune response to human immunodeficiency virus type
552 1. *Nat Immunol* **11**:1005-1013.
- 553 9. **Stavrou S, Blouch K, Kotla S, Bass A, Ross SR.** 2015. Nucleic acid recognition orchestrates the anti-
554 viral response to retroviruses. *Cell Host Microbe* **17**:478-488.
- 555 10. **Jakobsen MR, Bak RO, Andersen A, Berg RK, Jensen SB, Tengchuan J, Laustsen A, Hansen K,**
556 **Ostergaard L, Fitzgerald KA, Xiao TS, Mikkelsen JG, Mogensen TH, Paludan SR.** 2013. IFI16 senses
557 DNA forms of the lentiviral replication cycle and controls HIV-1 replication. *Proc Natl Acad Sci U S*
558 *A* **110**:E4571-4580.
- 559 11. **Monroe KM, Yang Z, Johnson JR, Geng X, Doitsh G, Krogan NJ, Greene WC.** 2014. IFI16 DNA
560 sensor is required for death of lymphoid CD4 T cells abortively infected with HIV. *Science* **343**:428-
561 432.
- 562 12. **Gao D, Wu J, Wu YT, Du F, Aroh C, Yan N, Sun L, Chen ZJ.** 2013. Cyclic GMP-AMP synthase is an
563 innate immune sensor of HIV and other retroviruses. *Science* **341**:903-906.
- 564 13. **Zhang Z, Yuan B, Bao M, Lu N, Kim T, Liu Y-J.** 2011. The helicase DDX41 senses intracellular DNA
565 mediated by the adaptor STING in dendritic cells. *Nature Immunology* **12**:959-965.
- 566 14. **Ishikawa H, Ma Z, Barber GN.** 2009. STING regulates intracellular DNA-mediated, type I
567 interferon-dependent innate immunity. *Nature* **461**:788-792.
- 568 15. **Saitoh T, Fujita N, Hayashi T, Takahara K, Satoh T, Lee H, Matsunaga K, Kageyama S, Omori H,**
569 **Noda T, Yamamoto N, Kawai T, Ishii K, Takeuchi O, Yoshimori T, Akira S.** 2009. Atg9a controls
570 dsDNA-driven dynamic translocation of STING and the innate immune response. *Proc Natl Acad*
571 *Sci U S A* **106**:20842-20846.
- 572 16. **Mukai K, Konno H, Akiba T, Uemura T, Waguri S, Kobayashi T, Barber GN, Arai H, Taguchi T.**
573 2016. Activation of STING requires palmitoylation at the Golgi. *Nat Commun* **7**:11932.
- 574 17. **Bhat N, Fitzgerald KA.** 2014. Recognition of cytosolic DNA by cGAS and other STING-dependent
575 sensors. *Eur J Immunol* **44**:634-640.
- 576 18. **Sun L, Wu J, Du F, Chen X, Chen ZJ.** 2013. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that
577 activates the type I interferon pathway. *Science* **339**:786-791.
- 578 19. **Wu J, Sun L, Chen X, Du F, Shi H, Chen C, Chen ZJ.** 2013. Cyclic GMP-AMP is an endogenous second
579 messenger in innate immune signaling by cytosolic DNA. *Science* **339**:826-830.
- 580 20. **Paludan SR, Bowie AG.** 2013. Immune sensing of DNA. *Immunity* **38**:870-880.
- 581 21. **Polprasert C, Schulze I, Sekeres MA, Makishima H, Przychodzen B, Hosono N, Singh J, Padgett**
582 **RA, Gu X, Phillips JG, Clemente M, Parker Y, Lindner D, Dienes B, Jankowsky E, Sauntharajah**
583 **Y, Du Y, Oakley K, Nguyen N, Mukherjee S, Pabst C, Godley LA, Churpek JE, Pollyea DA, Krug U,**
584 **Berdel WE, Klein HU, Dugas M, Shiraiishi Y, Chiba K, Tanaka H, Miyano S, Yoshida K, Ogawa S,**

- 585 **Muller-Tidow C, Maciejewski JP.** 2015. Inherited and Somatic Defects in DDX41 in Myeloid
586 Neoplasms. *Cancer Cell* **27**:658-670.
- 587 22. **Lewinsohn M, Brown AL, Weinel LM, Phung C, Rafidi G, Lee MK, Schreiber AW, Feng J, Babic M,**
588 **Chong CE, Lee Y, Yong A, Suthers GK, Poplawski N, Altree M, Phillips K, Jaensch L, Fine M,**
589 **D'Andrea RJ, Lewis ID, Medeiros BC, Pollyea DA, King MC, Walsh T, Keel S, Shimamura A, Godley**
590 **LA, Hahn CN, Churpek JE, Scott HS.** 2016. Novel germ line DDX41 mutations define families with
591 a lower age of MDS/AML onset and lymphoid malignancies. *Blood* **127**:1017-1023.
- 592 23. **Yoh SM, Schneider M, Seifried J, Soonthornvacharin S, Akleh RE, Olivieri KC, De Jesus PD, Ruan**
593 **C, de Castro E, Ruiz PA, Germanaud D, des Portes V, Garcia-Sastre A, Konig R, Chanda SK.** 2015.
594 PQBP1 Is a Proximal Sensor of the cGAS-Dependent Innate Response to HIV-1. *Cell* **161**:1293-
595 1305.
- 596 24. **Dutta D, Dutta S, Veettil MV, Roy A, Ansari MA, Iqbal J, Chikoti L, Kumar B, Johnson KE, Chandran**
597 **B.** 2015. BRCA1 Regulates IFI16 Mediated Nuclear Innate Sensing of Herpes Viral DNA and
598 Subsequent Induction of the Innate Inflammasome and Interferon-beta Responses. *PLoS Pathog*
599 **11**:e1005030.
- 600 25. **Li T, Diner BA, Chen J, Cristea IM.** 2012. Acetylation modulates cellular distribution and DNA
601 sensing ability of interferon-inducible protein IFI16. *Proc Natl Acad Sci U S A* **109**:10558-10563.
- 602 26. **Coffin JM, Hughes SH, Varmus HE (ed).** 1997. Retroviruses. CSHL Press, Cold Spring Harbor, NY.
- 603 27. **Blain SW, Goff SP.** 1995. Effects on DNA synthesis and translocation caused by mutations in the
604 RNase H domain of Moloney murine leukemia virus reverse transcriptase. *J Virol* **69**:4440-4452.
- 605 28. **Hwang CK, Svarovskaia ES, Pathak VK.** 2001. Dynamic copy choice: steady state between murine
606 leukemia virus polymerase and polymerase-dependent RNase H activity determines frequency of
607 in vivo template switching. *Proc Natl Acad Sci U S A* **98**:12209-12214.
- 608 29. **Konishi A, Hisayoshi T, Yokokawa K, Barrioluengo V, Menendez-Arias L, Yasukawa K.** 2014.
609 Amino acid substitutions away from the RNase H catalytic site increase the thermal stability of
610 Moloney murine leukemia virus reverse transcriptase through RNase H inactivation. *Biochem*
611 *Biophys Res Commun* **454**:269-274.
- 612 30. **Lindahl T, Gally JA, Edelman GM.** 1969. Properties of deoxyribonuclease 3 from mammalian
613 tissues. *J Biol Chem* **244**:5014-5019.
- 614 31. **Yuan F, Dutta T, Wang L, Song L, Gu L, Qian L, Benitez A, Ning S, Malhotra A, Deutscher MP,**
615 **Zhang Y.** 2015. Human DNA Exonuclease TREX1 Is Also an Exoribonuclease That Acts on Single-
616 stranded RNA. *J Biol Chem* **290**:13344-13353.
- 617 32. **Sauer JD, Sotelo-Troha K, von Moltke J, Monroe KM, Rae CS, Brubaker SW, Hyodo M, Hayakawa**
618 **Y, Woodward JJ, Portnoy DA, Vance RE.** 2011. The N-ethyl-N-nitrosourea-induced Goldenticket
619 mouse mutant reveals an essential function of Sting in the in vivo interferon response to *Listeria*
620 monocytogenes and cyclic dinucleotides. *Infect Immun* **79**:688-694.
- 621 33. **Zhang X, Shi H, Wu J, Zhang X, Sun L, Chen C, Chen ZJ.** 2013. Cyclic GMP-AMP containing mixed
622 phosphodiester linkages is an endogenous high-affinity ligand for STING. *Mol Cell* **51**:226-235.
- 623 34. **Stavrou S, Crawford D, Blouch K, Browne EP, Kohli RM, Ross SR.** 2014. Different modes of
624 retrovirus restriction by human APOBEC3A and APOBEC3G in vivo. *PLoS Pathog* **10**:e1004145.
- 625 35. **Kolokithas A, Rosenke K, Malik F, Hendrick D, Swanson L, Santiago ML, Portis JL, Hasenkrug KJ,**
626 **Evans LH.** 2010. The glycosylated Gag protein of a murine leukemia virus inhibits the antiretroviral
627 function of APOBEC3. *Journal of virology* **84**:10933-10936.
- 628 36. **Unterholzner L, Keating SE, Baran M, Horan KA, Jensen SB, Sharma S, Sirois CM, Jin T, Latz E,**
629 **Xiao TS, Fitzgerald KA, Paludan SR, Bowie AG.** 2010. IFI16 is an innate immune sensor for
630 intracellular DNA. *Nat Immunol* **11**:997-1004.

- 631 37. **Hansen K, Prabakaran T, Laustsen A, Jorgensen SE, Rahbaek SH, Jensen SB, Nielsen R, Leber JH,**
632 **Decker T, Horan KA, Jakobsen MR, Paludan SR.** 2014. *Listeria monocytogenes* induces IFN β
633 expression through an IFI16-, cGAS- and STING-dependent pathway. *EMBO J* **33**:1654-1666.
- 634 38. **Jankowsky E.** 2011. RNA helicases at work: binding and rearranging. *Trends Biochem Sci* **36**:19-
635 29.
- 636 39. **Jiang Y, Zhu Y, Liu ZJ, Ouyang S.** 2016. The emerging roles of the DDX41 protein in immunity and
637 diseases. *Protein Cell* doi:10.1007/s13238-016-0303-4.
- 638 40. **Rocak S, Linder P.** 2004. DEAD-box proteins: the driving forces behind RNA metabolism. *Nat Rev*
639 *Mol Cell Biol* **5**:232-241.
- 640 41. **Lewinsohn M, Brown AL, Weinel LM, Phung C, Rafidi G, Lee MK, Schreiber AW, Feng J, Babic M,**
641 **Chong CE, Lee Y, Yong A, Suthers GK, Poplowski N, Altree M, Phillips K, Jaensch L, Fine M,**
642 **D'Andrea RJ, Lewis ID, Medeiros BC, Pollyea DA, King MC, Walsh T, Keel S, Shimamura A, Godley**
643 **LA, Hahn CN, Churpek JN, Scott HS.** 2015. Novel germline DDX41 mutations define families with
644 a lower age of MDS/AML onset, and lymphoid malignancies. *Blood* doi:10.1182/blood-2015-10-
645 676098.
- 646 42. **Gringhuis SI, Hertoghs N, Kaptein TM, Zijlstra-Willems EM, Sarrami-Forooshani R, Sprokholt JK,**
647 **van Teijlingen NH, Kootstra NA, Booiman T, van Dort KA, Ribeiro CM, Drewniak A, Geijtenbeek**
648 **TB.** 2017. HIV-1 blocks the signaling adaptor MAVS to evade antiviral host defense after sensing
649 of abortive HIV-1 RNA by the host helicase DDX3. *Nat Immunol* **18**:225-235.
- 650 43. **Ma F, Li B, Liu SY, Iyer SS, Yu Y, Wu A, Cheng G.** 2015. Positive feedback regulation of type I IFN
651 production by the IFN-inducible DNA sensor cGAS. *J Immunol* **194**:1545-1554.
- 652 44. **Sewald X, Ladinsky MS, Uchil PD, Beloor J, Pi R, Herrmann C, Motamedi N, Murooka TT, Brehm**
653 **MA, Greiner DL, Shultz LD, Mempel TR, Bjorkman PJ, Kumar P, Mothes W.** 2015. Retroviruses
654 use CD169-mediated trans-infection of permissive lymphocytes to establish infection. *Science*
655 **350**:563-567.
- 656 45. **Akiyama H, Ramirez NG, Gudheti MV, Gummuluru S.** 2015. CD169-mediated trafficking of HIV to
657 plasma membrane invaginations in dendritic cells attenuates efficacy of anti-gp120 broadly
658 neutralizing antibodies. *PLoS Pathog* **11**:e1004751.
- 659 46. **Erikson E, Wratil PR, Frank M, Ambiel I, Pahnke K, Pino M, Azadi P, Izquierdo-Useros N,**
660 **Martinez-Picado J, Meier C, Schnaar RL, Crocker PR, Reutter W, Keppler OT.** 2015. Mouse Siglec-
661 1 Mediates trans-Infection of Surface-bound Murine Leukemia Virus in a Sialic Acid N-Acyl Side
662 Chain-dependent Manner. *J Biol Chem* **290**:27345-27359.
- 663 47. **Gray EE, Winship D, Snyder JM, Child SJ, Geballe AP, Stetson DB.** 2016. The AIM2-like Receptors
664 Are Dispensable for the Interferon Response to Intracellular DNA. *Immunity* **45**:255-266.
- 665 48. **Courreges MC, Burzyn D, Nepomnaschy I, Piazzon I, Ross SR.** 2007. Critical role of dendritic cells
666 in mouse mammary tumor virus *in vivo* infection. *J Virol* **81**:3769-3777.
- 667 49. **Wu C, Orozco C, Boyer J, Leglise M, Goodale J, Batalov S, Hodge CL, Haase J, Janes J, Huss JW,**
668 **3rd, Su AI.** 2009. BioGPS: an extensible and customizable portal for querying and organizing gene
669 annotation resources. *Genome Biol* **10**:R130.
- 670 50. **Lahaye X, Satoh T, Gentili M, Cerboni S, Conrad C, Hurbain I, El Marjou A, Lacabartz C, Lelievre**
671 **JD, Manel N.** 2013. The capsids of HIV-1 and HIV-2 determine immune detection of the viral cDNA
672 by the innate sensor cGAS in dendritic cells. *Immunity* **39**:1132-1142.
- 673 51. **Nakaya Y, Lilue J, Stavrou S, Moran EA, Ross SR.** 2017. AIM2-Like Receptors Positively and
674 Negatively Regulate the Interferon Response Induced by Cytosolic DNA. *MBio* **8**.
- 675 52. **Schoggins JW, MacDuff DA, Imanaka N, Gainey MD, Shrestha B, Eitson JL, Mar KB, Richardson**
676 **RB, Ratushny AV, Litvak V, Dabelic R, Manicassamy B, Aitchison JD, Aderem A, Elliott RM,**
677 **Garcia-Sastre A, Racaniello V, Snijder EJ, Yokoyama WM, Diamond MS, Virgin HW, Rice CM.**

- 678 2014. Pan-viral specificity of IFN-induced genes reveals new roles for cGAS in innate immunity.
679 Nature **505**:691-695.
- 680 53. **Okeoma CM, Lovsin N, Peterlin BM, Ross SR.** 2007. APOBEC3 inhibits mouse mammary tumour
681 virus replication in vivo. Nature **445**:927-930.
- 682 54. **Fan H, Chute H, Chao E, Feuerman M.** 1983. Construction and characterization of Moloney murine
683 leukemia virus mutants unable to synthesize glycosylated gag polyprotein. Proc Natl Acad Sci USA
684 **80**:5965-5969.
- 685 55. **Feuerman MH, Davis BR, Pattengale PK, Fan H.** 1985. Generation of a recombinant Moloney
686 murine leukemia virus carrying the v-src gene of avian sarcoma virus: transformation in vitro and
687 pathogenesis in vivo. J Virol **54**:804-816.
- 688 56. **Lutz MB, Kukutsch N, Ogilvie AL, Rossner S, Koch F, Romani N, Schuler G.** 1999. An advanced
689 culture method for generating large quantities of highly pure dendritic cells from mouse bone
690 marrow. J Immunol Methods **223**:77-92.
- 691 57. **Hornung V, Bauernfeind F, Halle A, Samstad EO, Kono H, Rock KL, Fitzgerald KA, Latz E.** 2008.
692 Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal
693 destabilization. Nat Immunol **9**:847-856.
- 694 58. **Okeoma CM, Petersen J, Ross SR.** 2009. Expression of murine APOBEC3 alleles in different mouse
695 strains and their effect on mouse mammary tumor virus infection. J Virol **83**:3029-3038.
- 696 59. **Beck-Engeser GB, Eilat D, Harrer T, Jack HM, Wabl M.** 2009. Early onset of autoimmune disease
697 by the retroviral integrase inhibitor raltegravir. Proc Natl Acad Sci U S A **106**:20865-20870.
- 698 60. **Brunette RL, Young JM, Whitley DG, Brodsky IE, Malik HS, Stetson DB.** 2012. Extensive
699 evolutionary and functional diversity among mammalian AIM2-like receptors. The Journal of
700 experimental medicine **209**:1969-1983.
- 701 61. **Harada F, Peters GG, Dahlberg JE.** 1979. The primer tRNA for Moloney murine leukemia virus
702 DNA synthesis. Nucleotide sequence and aminoacylation of tRNA^{Pro}. J Biol Chem **254**:10979-
703 10985.
- 704

705 Fig. Legends

706

707 **Fig. 1.** DDX41 and IFI203 work together with cGAS for the maximal anti-viral response. A)

708 Knockdown of STING, DDX41 and IFI203 in cGAS/APOBEC3 double knockout BMDMs and BMDCs.

709 Cells were transfected with the indicated siRNAs and 48hrs later cells were infected with MLV. At

710 2 hpi, the cells were harvested and examined for IFN β RNA levels. Knockdown verification of the

711 genes is shown in Fig. S1A. Values are shown as mean \pm STDs of three experiments, each with

712 macrophages and DCs from a different mouse. P values were determined by unpaired T-tests

713 (NS, not significant; *, $p \leq 0.05$; **, $p \leq 0.01$). B) Diagram shows the cGAS-cGAMP-STING pathway.

714 The dotted line represents the possible points of DDX41 action; cGAMP addition would rescue

715 DDX41 knockdown if it acted at (a) but not if DDX41 acted at (b) in the pathway. The red lines
716 represent viral reverse transcripts. C) cGAMP rescues cGAS but not STING, DDX41 or IFI203
717 knockdown. NR9456 macrophages were transfected with the indicated siRNAs and 24 hr later,
718 transfected with cGAMP. At 18 hr post-cGAMP treatment, the cells were infected with MLV; IFN β
719 RNA levels measured at 2 hpi. Values are shown as mean \pm STDs of three experiments.
720 Knockdown verification of the genes is shown in Fig. S1B. Mock denotes mock-infected cells.

721

722 **Fig. 2.** DDX41 acts upstream of IRF3 and TBK1. IRF3 (left panel) and TBK (right panel)
723 phosphorylation induced by MLV infection requires DDX41, cGAS and STING. NR9456 cells were
724 transfected with the indicated siRNAs as well as Trex1 siRNA and 48hr later, infected with MLV
725 for 2 hr. Control cells were infected but received only control siRNA. The LPS treatments were for
726 6 hr. Equal amounts of protein from the cells were analyzed using the indicated antibodies. Mock
727 denotes mock-infected cells. The TBK1 and IRF3 experiments were performed twice. Shown are
728 representative western blots.

729

730 **Fig. 3.** DDX41 preferentially binds RNA/DNA hybrids. A) Diagram of the tRNA/LTR (P_R and P_{tRNA})
731 and strong stop primers (P_R and P_{U5}) used to amplify the bound nucleic acid in (B). Red box
732 represents the newly synthesized viral DNA; shown below is the viral RNA. Abbreviations: vRNA,
733 viral RNA; PBS, primer binding site. B) DNA pulldown assays with extracts from 293T MCAT-1 cells
734 transfected with the indicated constructs and infected with MLV. Shown is the mean of 4
735 independent experiments \pm STD. **, $p \leq 0.01$ (unpaired T-test); NS, not significant. C) DNA
736 pulldown assays were conducted as in (B), except that prior to the reverse transcription/RT-qPCR,

737 the nucleic acids were treated with the indicated nucleases. Shown is the average of two
738 experiments done in triplicate. The numbers above the columns show percent nucleic acid
739 pulldown relative to no nuclease.

740

741 **Fig. 4.** MLV^{D542N} reverse transcripts are sensed by DDX41. A) Diagram of the early stages of
742 reverse transcription. The RNaseH^{D542N} mutation allows initial reverse transcription but because
743 of the loss of RNaseH activity, strong stop DNA cannot translocate to the 3' end of the viral RNA
744 to initiate transcription of the full length viral dsDNA; the tRNA primer is also not degraded. P_{3'R}
745 and P_{3'L} denote the 3'LTR primers used in panel B. Abbreviations: PBS, primer binding site; ppt,
746 polypurine tract; ssDNA, single-strand DNA; ds, double-strand DNA. B) NR9456 cells treated with
747 the indicated siRNAs were infected with D542N or wildtype virus and 2 hpi, RNA was subjected
748 to reverse transcribed-qPCR with primers to the tRNA-containing RNA/DNA hybrid (P_R and P_{tRNA},
749 Fig. 3A), while DNA was subjected to qPCR with strong-stop DNA (P_R and P_{U5}, Fig. 3A) or late
750 reverse transcripts (P_{3'R} and P_{3'L} primers, Fig. 4A). Shown is the mean ± STDs of 3 independent
751 experiments. *, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001 (unpaired T-test). C) Recognition of RNA-DNA
752 hybrids requires DDX41. NR9456 cells (left panel) or BMDCs (right panel) were transfected with
753 the indicated siRNAs, infected with wild type MLV or MLV^{D542N} for 2 hr and the levels of IFNβ
754 RNA were measured. Shown is the mean ± STD of 3 independent experiments. *, p ≤ 0.05; **, p ≤
755 0.01; ***, p ≤ 0.001 (unpaired T-test). Knockdown of the genes is shown in Fig. S3. Mock denotes
756 mock-infected cells.

757

758 **Fig. 5.** Characterization of DDX41 knockout BMDMs and BMDCs. A) Basal expression of the
759 different sensors in wild type BMDCs and BMDMs. Shown are the average and STDs of cells
760 isolated from 3 different mice. Inset shows western blot of 40 μ g each of extracts from BMDMs
761 and BMDCs, probed with antisera against DDX41, cGAS and GAPDH. B) Relative expression of
762 DDX41 in BMDMs and BMDCs. Forty μ g of protein from cells isolated from mice of the indicated
763 genotypes were analyzed by western blot with antisera to the indicated proteins. Gels are
764 representative of 3 independent experiments. Averages from the 3 experiments are shown in in
765 Supplementary Fig. 4B.

766

767 **Fig. 6.** MLV and HIV induce a DDX41-dependent IFN β response in BMDMs and BMDCs. A) BMDMs
768 and BMDCs isolated from mice of the indicated genotypes were infected with MLV and at 2 hr pi,
769 IFN β levels were measured. The data in the graph are the average of 3 different experiments,
770 each with macrophages and DCs from a different mouse. *, $p \leq 0.05$; **, $p \leq 0.01$; ***, $p \leq 0.001$
771 (unpaired T-test). Verification of the knockdown is shown in Fig. S5B. ELISAs measuring IFN β
772 protein are shown in Fig. S5A. B) HIV pseudotype infection in cGAS and DDX41 KO BMDMs and
773 relative infection of BMDMs and BMDCs by MLV. HIV cores pseudotyped with ecotropic MLV
774 glycoproteins were used to infect BMDMs (left panel) or BMDCs (right panel) from mice of the
775 indicated genotypes. Trex1 knockdowns are shown in the right panels. Shown are the average of
776 3 independent experiments. ***, $p \leq 0.001$; ****, $p \leq 0.0001$ (unpaired T-test). C) DCs and
777 macrophages were isolated from MLV-infected mice at 16 dpi and levels of integrated MLV were
778 determined by qPCR. **, $p \leq 0.01$. Mock denotes mock-infected cells.

779

780 **Fig. 7.** *In vivo* control of retrovirus infection requires both cGAS and DDX41. A) Mice of the
781 indicated genotype received footpad injections of siRNAs. Forty-eight hrs post-injection, the mice
782 were injected with of MLV. RNA was harvested from the draining lymph node at 24 hpi and
783 analyzed for MLV. Knockdown verification is shown in Fig. S7. ****, $p \leq 0.00001$; ***, $p \leq 0.0001$;
784 **, $p \leq 0.001$; *, $p \leq 0.01$ B). (unpaired T-test). Number of mice in each group is shown above the
785 graph. B) Newborn mice of the indicated genotypes were inoculated with MLV. At 16 days pi,
786 virus titers in spleen were measured. Each point represents an individual mouse. The numbers of
787 mice analyzed in each group is shown on the graph; each of the groups of mice came from 4 – 10
788 independent litters. Horizontal bars represent the average. **, $p \leq 0.001$, NS, not significant (Mann
789 Whitney T-test).
790

Supporting Information

791 **Fig. S1.** Knockdown verification. Related to Fig. 1. A) Knockdown of genes in Fig. 1A. The
792 knockdown of the three target genes (DDX41, IFI203 and STING) were all done in the presence of
793 Trex1 knockdown, as indicated in the Fig. 1 legend. B) Knockdown of genes in Fig. 1C. See Fig. 1
794 legend for details.

795

796 **Fig. S2.** DDX41 senses DNA in the cytoplasm via its DEAD domain. Related to Fig. 2. A) Increasing
797 nuclear dsDNA by inhibiting proviral DNA integration has no effect on DDX41-mediated sensing.
798 NR9456 cells were pretreated with raltegravir (200nM) and then infected with MLV (MOI=2) in
799 the presence of drug. DNA and RNA were isolated from infected cells 2 hpi and analyzed for
800 unintegrated viral DNA (2LTR) or IFN β RNA levels. Values are shown as mean \pm STDs of three
801 experiments. P values were determined by an unpaired T-test. (*, $p \leq 0.05$; **, $p \leq 0.01$; ***, $p \leq$
802 0.001). Inset shows levels of Trex1 RNA knockdown.

803

804 **Fig. S3.** Knockdown verification. Related to Fig. 4. A) Knockdown of genes in Fig. 4C. See Fig. 4
805 legend for details.

806

807 **Fig. S4.** Characterization of DDX41 KO mice. Related to Fig. 5 and 6. A) Map of the DDX41 locus
808 and inserted lox P sites. Expression of Cre recombinase results in the deletion of exons 7 - 9. B)
809 Quantification of DDX41, cGAS and STING protein in various knockout mouse cells. Shown is the
810 mean \pm STD for 3 independent western blots of cells from 3 different mice of each strain. *, p

811 ≤ 0.05 compared to BL/6, STING^{gt/gt} and CD11cCreDDX41 (unpaired T-Test). C) Basal IFN β RNA
812 levels in DDX41 KO BMDMs and BMDCs. RNA was isolated from BMDMs of 3 mice and BMDCs of
813 2 mice each of the indicated genotypes and qPCR was performed for IFN β levels, using a standard
814 curve to measure relative levels. Shown is the mean +/- STD. Abbreviations: ND, not done. D)
815 PBMCs from 4 mice of each genotype were stained with conjugated anti-CD11c (DCs) or anti-
816 F4/80 (macrophages) antibodies and analyzed by FACS. E) Treatment of DDX41 KO BMDMs and
817 BMDCs with different ligands. BMDMs and BMDCs from the cGAS, LyCre DDX41 and CD11cCre-
818 DDX41 KO and STING^{gt/gt} mice were treated with the indicated ligands, as described in
819 Supplemental Experimental Procedures. RNA was isolated after 6 hr of treatment for all ligands
820 and subjected to RT-qPCR. Shown is the average of 2 experiments (triplicate technical replicates)
821 with cells isolated from different mice.

822

823 **Fig. S5.** Loss of DDX41 decreases the IFN response to MLV and HIV infection. Related to Fig. 6. A)
824 BMDMs and BMDCs from C57, cGAS, LyCre-DDX41 and CD11cCre-DDX41 were treated siCont or
825 siTrex and then infected with MLV^{glycoGag}. Four hrs later supernatants were used to perform an
826 ELISA for IFN β levels. Shown are the average of 3 independent experiments. ****, $p \leq 0.0001$
827 (unpaired T-test). B) Verification of Trex1 knockdown in BMDCs and BMDMs in Fig. 6A. C)
828 Verification of the knockdowns in BMDMs and BMDCs in Fig. 6B.

829

830 **Fig. S6.** BMDCs are more infected by MLV than BMMS. Related to Fig. 6. BMDMs and BMDCs
831 from mice of the indicated genotypes were infected with MLV and at 24 and 48 hr pi infection,
832 DNA was isolated from cells and subjected to qPCR, using one primer to mouse genomic DNA and



833 the other to the viral long terminal repeat. Values are shown and mean \pm SEM of 2 experiments
834 done for each cell type. highlighted boxes refer to homozygous and white boxes to heterozygous
835 DDX41 tissue-specific knockouts, gray boxes refer to WT mice.

836


837 **Fig. S7.** *In vivo* control of retrovirus infection requires both cGAS and DDX41. Related to Fig. 7. A)
838 Knockdown verification of the *in vivo* siRNA experiment presented in Fig. 7A. B) Genotypes of the
839 mice tested for MLV infection in Fig. 7B. Parental mice were Cre^{+/-}, DX41^{+/-}. Cre refers to either
840 LyCre or CD11cCre, as indicated in the text. Yellow highlighted boxes refer to homozygous and
841 white boxes to heterozygous DDX41 tissue-specific knockouts, gray boxes refer to WT mice.

cGAS/APOBEC3 KO


A




B




C




A








B





C






A**B**


A



C



A



B

